openPR Logo
Press release

Rosa Diabetes PhysioPD™ Collaboration with Pfizer to be Presented at World PK/PD Summit

04-22-2011 09:59 AM CET | Science & Education

Press release from: Rosa and Co

Rosa Logo

Rosa Logo

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Diabetes PhysioPD™ collaboration with Pfizer will be presented at the Biorbis World PK/PD Summit in Cambridge, MA April 26-29, 2011. David A. Tess, Principal Scientist, of Pfizer Inc. will be presenting a 30-minute scientific presentation entitled “Creating and Using a Physiological Model to Support Development of a GPR119 Agonist Diabetes Therapy”. The presentation will describe the development, testing, and use of a custom-designed Diabetes PhysioPD model, including use of the model to clarify mechanisms of action, support compound selection, select First-In-Human doses, and predict longer-term (HbA1c lowering) clinical outcomes. The model was built using literature data and only limited summary pharmacokinetic data from a competitor’s short-duration phase I trial. The presentation will also highlight the extensive testing regime to which the PhysioPD model was subjected.

“We are pleased to present results from our collaboration with Pfizer. They are leaders in the adoption of systems pharmacology modeling, and this work represents some of our early successes in this process,” said Dr. Ron Beaver, Rosa’s Founder and CEO.

Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.

Rosa & Co. LLC
751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rosa Diabetes PhysioPD™ Collaboration with Pfizer to be Presented at World PK/PD Summit here

News-ID: 172107 • Views:

More Releases for PhysioPD

GlaxoSmithKline and Rosa Present Psoriasis Collaboration Results at 17th Interna …
PhysioPD™ modeling collaboration in psoriasis to be presented September 9-13, 2012. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Psoriasis PhysioPD collaboration with Stiefel, a GSK Company, will be presented at the 17th International Inflammation Research Association Conference in Lake George, NY, September 9-13th, 2012. Dr. Betty Hussey, Director, Clinical Pharmacology of GSK will present a poster
Rosa Announces Publication of its PhysioPD™ Model Qualification Method and Ser …
Series of Seminars and Workshops to be held in 2012 across the US and in Europe Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the publication of its Model Qualification Method (“MQM”) in the White Paper, “Facilitating Drug Discovery and Development with Mechanistic Physiological Models that are ‘Fit for Purpose.’” Rosa created the MQM to enable the broader adoption and use
Biopontis Alliance Fund and Rosa Announce Strategic Relationship for Early Stage …
Collaboration will combine Rosa’s PhysioPD™ modeling & simulation capabilities with Biopontis’ innovative asset sourcing and financial structure to improve early drug development productivity Biopontis Alliance, Inc, (www.biopontisalliance.com) a unique firm combining early-stage capital investment with early-stage drug development, today announced that it has completed a strategic patrtnership agreement with Rosa and Co. (www.rosaandco.com), an advisory firm with leading expertise in PhysioPD and PKPD drug-disease modeling and simulation. Rosa’s capabilities will be
Rosa’s Toufigh Gordi to Present at 2nd Annual Pediatric Pharmacology Conferenc …
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that its Dr. Toufigh Gordi, President of PKPD and Clinical Pharmacology Services, will present the results of an Accelerator Mass Spectrometry (AMS) microdosing study in infants at the 2nd Annual Pediatric Pharmacology Conference in Philadelphia, PA on January 26, 2012. Dr. Gordi will give a 30 minute scientific presentation entitled “Pediatric PK
Rosa’s Christina Friedrich to Lead Model Qualification Workshop at ICSB 2011
The Model Qualification Method is a rigorous, systematic analysis of model relevance, uncertainty, variability, and consistency with data to ensure drug discovery/development models are “fit for purpose” Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will be leading a workshop on its Model Qualification Method (MQM) at the 12th International Conference on Systems Biology (ICSB), the major event for
Dr. Rebecca Baillie to Describe PhysioPD™ Model Construction and Testing in Ro …
Rosa & Co. LLC today announced that Dr. Rebecca Baillie will present a webinar “How to build a PhysioPD model” on June 20, 2011 at 1:00 pm EDT (GMT -5:00) as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science